Growing evidence suggests a complex interplay between GLP-1 and eCBome in regulating metabolism, gut homeostasis, and inflammation, making them promising therapeutic targets for IBD-associated metabolic disorders [173,178,179,180]. This evidence concerns the gene GLP1R and metabolic disease.